申请人:——
公开号:US03987042A1
公开(公告)日:1976-10-19
Phenothiazine derivatives are described of the formula ##SPC1## In which X.sub.1 and X.sub.2, which may be the same or different, are H, R, F, Cl, Br, OR, CN, --COR, CH.sub.3, --S--R, --SOR, --SO.sub.2 R or --SO.sub.2 N(CH.sub.3).sub.2, where R is an alkyl group having from 1 to 4 carbon atoms, and the quinuclidine ring is substituted by the group --(CH.sub.2).sub.x -- in the 2- or 3- position, x being 1 or 2 when said group is substituted in the 2-position and being 0 or 1 when said group is substituted in the 3-position (because of electronic hindrance), and their acid addition and quaternary ammonium salts, have valuable pharmacological properties. In particular, these compounds have anti-histaminic, anti-cholinergic, adrenolytic, neuro-sedative, tranquillizing and/or spasmolytic properties. These compounds are prepared by condensing an appropriate phenothiazine with a quinuclidine derivative of the formula ##SPC2## In which x has the above-stated meaning and Z is a halogen atom or a reactive ester group.
苯噻嗪衍生物的结构式描述如下:##SPC1## 其中X.sub.1和X.sub.2,可以相同也可以不同,为H、R、F、Cl、Br、OR、CN、--COR、CH.sub.3、--S--R、--SOR、--SO.sub.2 R或--SO.sub.2 N(CH.sub.3).sub.2,其中R是具有1至4个碳原子的烷基基团,奎尼啉环被羰基--(CH.sub.2).sub.x-- 取代在2-或3-位置,当该基团在2-位置取代时,x为1或2,当该基团在3-位置取代时,x为0或1(由于电子障碍),它们的酸盐和季铵盐具有有价值的药理特性。特别是,这些化合物具有抗组胺、抗胆碱能、肾上腺抑制、神经镇静、镇定和/或解痉作用。这些化合物是通过将适当的苯噻嗪与结构式为##SPC2## 的奎尼啉衍生物缩合而制备的,其中x具有上述定义,Z为卤原子或活性酯基。